Allergan's Vistabel receives Positive Opinion from ANSM

Allergan's Vistabel receives positive opinion from ANSM for treatment of moderate to severe forehead lines in adult patients in 30 European countries. 

Global biopharmaceutical company Allergan Plc announced that Vistabel has recieved a positive opinion from the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) for the temporary improvement in the appearance of moderate to severe forehead lines in adults when the severity of the facial lines has an important psychological impact. This is an important step towards securing national licenses in the 28 countries of the European Union as well as Norway and Iceland.

This Positive Opinion means that Vistabel is indicated for the temporary improvement in the appearance of moderate to severe forehead lines and/or glabellar (frown) lines and/or crow's feet lines in adult patients. This Positive Opinion is specific to Allergan's botulium toxin type A product and is based on allergan's international phase III studies in forehead and glabellar lines treated simultaneously.

“Allergan is proud to continue its leadership in medical aesthetics and this additional indication for VISTABEL^® broadens the options available to practitioners when treating forehead lines. The appearance of horizontal lines caused by muscle contraction, especially on the forehead, can have a considerable impact on patients. Once licensed, Allergan will be able to train physicians effectively to improve the appearance of upper facial lines that worry their patients,” said Marc Princen, Executive Vice President and President, International Business at Allergan.